New advice on modified-release morphine

The Royal Pharmaceutical Society has reviewed its position on brand-name prescribing of modified-release morphine preparations and fentanyl patches.

The society’s practice committee decided there was no compelling evidence to show that pain control was affected by switching between brands of modified-release morphine preparations with the same release profile. 

There was also no evidence of a difference in the rate of delivery between brands of fentanyl patches when used in accordance with the product licence, says the society. 

As a result, the practice committee does not recommend routine brand name prescribing of modified-release morphine preparations and fentanyl patches. 

The committee warned that pharmacists should aim to prevent unintentional changes of the brand supplied to patients. If the brand of strong modified-release morphine preparations needs to be changed, then the pharmacist should ensure that the patient and the patient’s carers understand and accept the need for change. 

Pharmacists were also reminded: ‘There are important differences between matrix patches and reservoir patches. Reservoir patches of fentanyl should never be cut to deliver a smaller dose because this disrupts the controlled-release mechanism.’

For general enquiries contact the society’s practice and quality improvement directorate at practice@rpsgb.org.

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register

Already registered?

Sign in

Before commenting please read our rules for commenting on articles.

If you see a comment you find offensive, you can flag it as inappropriate. In the top right-hand corner of an individual comment, you will see 'flag as inappropriate'. Clicking this prompts us to review the comment. For further information see our rules for commenting on articles.

comments powered by Disqus